Does the media refer more to REGN or ALNY?

In the previous week, Regeneron Pharmaceuticals had 44 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 98 mentions for Regeneron Pharmaceuticals and 54 mentions for Alnylam Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.69 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 34 Very Positive mention(s) 9 Positive mention(s) 42 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Alnylam Pharmaceuticals 9 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 13 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to ARGX or ALNY?

In the previous week, Alnylam Pharmaceuticals had 21 more articles in the media than argenex. MarketBeat recorded 54 mentions for Alnylam Pharmaceuticals and 33 mentions for argenex. argenex's average media sentiment score of 0.87 beat Alnylam Pharmaceuticals' score of 0.06 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 15 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 9 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 13 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media favor RVMD or ALNY?

In the previous week, Alnylam Pharmaceuticals had 33 more articles in the media than Revolution Medicines. MarketBeat recorded 54 mentions for Alnylam Pharmaceuticals and 21 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.39 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 18 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 9 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 13 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media favor ALNY or NTRA?

In the previous week, Alnylam Pharmaceuticals had 20 more articles in the media than Natera. MarketBeat recorded 54 mentions for Alnylam Pharmaceuticals and 34 mentions for Natera. Natera's average media sentiment score of 0.67 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 9 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 13 Negative mention(s) 2 Very Negative mention(s) Neutral Natera 23 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BIIB or ALNY?

In the previous week, Biogen had 14 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 68 mentions for Biogen and 54 mentions for Alnylam Pharmaceuticals. Biogen's average media sentiment score of 0.91 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 36 Very Positive mention(s) 5 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 9 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 13 Negative mention(s) 2 Very Negative mention(s) Neutral

Alnylam Pharmaceuticals (ALNY) Competitors

$216.61 +11.09 (+5.40%)

As of 11:59 AM Eastern

Compare

ALNY vs. REGN, ARGX, RVMD, NTRA, and BIIB

Should you buy Alnylam Pharmaceuticals stock or one of its competitors? MarketBeat compares Alnylam Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alnylam Pharmaceuticals include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Revolution Medicines (RVMD), Natera (NTRA), and Biogen (BIIB). These companies are all part of the "biotechnology" industry.

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Regeneron Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.64	$4.50B	$40.46	18.90
Alnylam Pharmaceuticals	$3.71B	7.80	$313.75M	$5.38	40.26

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Regeneron Pharmaceuticals had 44 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 98 mentions for Regeneron Pharmaceuticals and 54 mentions for Alnylam Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.69 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	34 Very Positive mention(s)	9 Positive mention(s)	42 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	9 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	13 Negative mention(s)	2 Very Negative mention(s)	Neutral

Regeneron Pharmaceuticals presently has a consensus price target of $796.08, suggesting a potential upside of 4.10%. Alnylam Pharmaceuticals has a consensus price target of $404.57, suggesting a potential upside of 86.77%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.88

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 104.81% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Alnylam Pharmaceuticals	15.26%	104.81%	14.71%

Regeneron Pharmaceuticals has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to argenex?

argenex (NASDAQ:ARGX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

argenex has higher revenue and earnings than Alnylam Pharmaceuticals. argenex is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.23	$1.29B	$26.04	31.90
Alnylam Pharmaceuticals	$3.71B	7.80	$313.75M	$5.38	40.26

In the previous week, Alnylam Pharmaceuticals had 21 more articles in the media than argenex. MarketBeat recorded 54 mentions for Alnylam Pharmaceuticals and 33 mentions for argenex. argenex's average media sentiment score of 0.87 beat Alnylam Pharmaceuticals' score of 0.06 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	15 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	9 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	13 Negative mention(s)	2 Very Negative mention(s)	Neutral

60.3% of argenex shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

argenex has a net margin of 32.19% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 104.81% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Alnylam Pharmaceuticals	15.26%	104.81%	14.71%

argenex currently has a consensus target price of $1,056.89, indicating a potential upside of 27.21%. Alnylam Pharmaceuticals has a consensus target price of $404.57, indicating a potential upside of 86.77%. Given Alnylam Pharmaceuticals' higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.88

Summary

argenex beats Alnylam Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Revolution Medicines' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 104.81% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Alnylam Pharmaceuticals	15.26%	104.81%	14.71%

Alnylam Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A
Alnylam Pharmaceuticals	$3.71B	7.80	$313.75M	$5.38	40.26

Revolution Medicines currently has a consensus target price of $144.67, suggesting a potential downside of 21.46%. Alnylam Pharmaceuticals has a consensus target price of $404.57, suggesting a potential upside of 86.77%. Given Alnylam Pharmaceuticals' higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.88

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Alnylam Pharmaceuticals had 33 more articles in the media than Revolution Medicines. MarketBeat recorded 54 mentions for Alnylam Pharmaceuticals and 21 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.39 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	18 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	9 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	13 Negative mention(s)	2 Very Negative mention(s)	Neutral

Revolution Medicines has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Revolution Medicines on 10 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Natera?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

Alnylam Pharmaceuticals presently has a consensus target price of $404.57, suggesting a potential upside of 86.77%. Natera has a consensus target price of $267.83, suggesting a potential downside of 0.78%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.88
Natera	2 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	3 Strong Buy rating(s)	2.82

In the previous week, Alnylam Pharmaceuticals had 20 more articles in the media than Natera. MarketBeat recorded 54 mentions for Alnylam Pharmaceuticals and 34 mentions for Natera. Natera's average media sentiment score of 0.67 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	9 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	13 Negative mention(s)	2 Very Negative mention(s)	Neutral
Natera	23 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	7.80	$313.75M	$5.38	40.26
Natera	$2.31B	16.76	-$208.16M	-$1.63	N/A

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Natera's net margin of -9.05%. Alnylam Pharmaceuticals' return on equity of 104.81% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	104.81%	14.71%
Natera	-9.05%	-14.74%	-10.27%

Summary

Alnylam Pharmaceuticals beats Natera on 11 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Biogen?

Biogen (NASDAQ:BIIB) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Biogen's net margin of 8.32%. Alnylam Pharmaceuticals' return on equity of 104.81% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Alnylam Pharmaceuticals	15.26%	104.81%	14.71%

Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

87.9% of Biogen shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biogen has higher revenue and earnings than Alnylam Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.02	$1.29B	$5.65	35.78
Alnylam Pharmaceuticals	$3.71B	7.80	$313.75M	$5.38	40.26

Biogen currently has a consensus target price of $223.36, indicating a potential upside of 10.48%. Alnylam Pharmaceuticals has a consensus target price of $404.57, indicating a potential upside of 86.77%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.88

In the previous week, Biogen had 14 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 68 mentions for Biogen and 54 mentions for Alnylam Pharmaceuticals. Biogen's average media sentiment score of 0.91 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	36 Very Positive mention(s)	5 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	9 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	13 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Alnylam Pharmaceuticals beats Biogen on 11 of the 17 factors compared between the two stocks.

Get Alnylam Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALNY vs. The Competition

Export

Metric	Alnylam Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.95B	$3.52B	$6.79B	$12.63B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	40.21	7.39	282.14	25.05
Price / Sales	7.80	1,212.47	573.43	80.07
Price / Cash	73.50	44.80	28.60	46.71
Price / Book	36.28	17.11	11.09	6.19
Net Income	$313.75M	-$12.56M	$3.49B	$347.61M
7 Day Performance	-22.19%	-0.59%	0.42%	0.74%
1 Month Performance	-30.75%	-7.44%	-4.33%	-3.72%
1 Year Performance	-46.09%	49.84%	63.09%	20.27%

Alnylam Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALNY Alnylam Pharmaceuticals	4.6995 of 5 stars	$216.61 +5.4%	$404.57 +86.8%	-48.9%	$28.95B	$3.71B	40.21	2,770	Trending News Analyst Forecast
REGN Regeneron Pharmaceuticals	3.8855 of 5 stars	$757.49 +2.6%	$793.13 +4.7%	+36.5%	$80.08B	$14.34B	18.46	15,410	Trending News Earnings Report Dividend Announcement Analyst Forecast
ARGX argenex	4.5986 of 5 stars	$857.95 -1.7%	$1,056.89 +23.2%	+26.7%	$53.67B	$4.25B	32.95	1,863
RVMD Revolution Medicines	1.9733 of 5 stars	$189.17 -1.6%	$144.67 -23.5%	+412.0%	$40.23B	N/A	N/A	250	Positive News Upcoming Earnings
NTRA Natera	2.7301 of 5 stars	$266.18 -1.3%	$267.83 +0.6%	+99.0%	$38.14B	$2.31B	N/A	6,140	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALNY) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. REGN, ARGX, RVMD, NTRA, and BIIB

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Summary

How does Alnylam Pharmaceuticals compare to argenex?

Summary

How does Alnylam Pharmaceuticals compare to Revolution Medicines?

Summary

How does Alnylam Pharmaceuticals compare to Natera?

Summary

How does Alnylam Pharmaceuticals compare to Biogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. REGN, ARGX, RVMD, NTRA, and BIIB

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Which has stronger earnings & valuation, REGN or ALNY?

Do institutionals and insiders hold more shares of REGN or ALNY?

Does the media refer more to REGN or ALNY?

Do analysts recommend REGN or ALNY?

Is REGN or ALNY more profitable?

Which has more volatility & risk, REGN or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to argenex?

Which has more risk and volatility, ARGX or ALNY?

Which has higher valuation and earnings, ARGX or ALNY?

Does the media refer more to ARGX or ALNY?

Do institutionals and insiders believe in ARGX or ALNY?

Is ARGX or ALNY more profitable?

Do analysts rate ARGX or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to Revolution Medicines?

Is RVMD or ALNY more profitable?

Which has better valuation and earnings, RVMD or ALNY?

Do analysts rate RVMD or ALNY?

Do institutionals & insiders hold more shares of RVMD or ALNY?

Does the media favor RVMD or ALNY?

Which has more risk & volatility, RVMD or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to Natera?

Which has more volatility & risk, ALNY or NTRA?

Do analysts prefer ALNY or NTRA?

Does the media favor ALNY or NTRA?

Which has preferable valuation and earnings, ALNY or NTRA?

Do institutionals & insiders hold more shares of ALNY or NTRA?

Is ALNY or NTRA more profitable?

Summary

How does Alnylam Pharmaceuticals compare to Biogen?

Is BIIB or ALNY more profitable?

Which has more volatility & risk, BIIB or ALNY?

Do insiders and institutionals hold more shares of BIIB or ALNY?

Which has higher earnings & valuation, BIIB or ALNY?

Do analysts recommend BIIB or ALNY?

Does the media refer more to BIIB or ALNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools